Beta-Blockers and Carbonic Anhydrase Inhibitors: Turning Down Aqueous Production

The tap, not the drain

Intraocular pressure is a balance between aqueous made and aqueous drained. The ciliary body — a ring of tissue behind the iris — secretes aqueous humour, the clear fluid that inflates the front of the eye and feeds the avascular cornea and lens. That fluid drains out mainly through the trabecular meshwork. Pressure rises when either too much is made or too little escapes. The prostaglandin analogues covered in the companion chapter attack the drain, boosting uveoscleral outflow. The two classes here attack the source: they tell the ciliary epithelium to make less fluid in the first place. Suppress production and, drain unchanged, the pressure falls. This is why aqueous suppressants combine so naturally with a prostaglandin — one turns down the tap, the other opens the drain, and their effects add up.

Topical beta-blockers: the old first-line

The ciliary epithelium carries beta-adrenergic receptors, and their tonic stimulation drives aqueous secretion through a cAMP second-messenger cascade — the same beta-receptor biology taught in the Autonomic Nervous System chapter. Block those receptors and cAMP-driven secretion falls, cutting aqueous production by roughly a quarter to a third. Timolol, a non-selective beta-blocker (β1 and β2), was for decades THE standard drop and the benchmark every new glaucoma drug was measured against. It still holds a place as a cheap, effective add-on, though prostaglandins have displaced it as first-line because they lower pressure more and lack the systemic risk. Betaxolol is the important cousin: a β1-selective blocker. It lowers pressure slightly less than timolol but is far safer in the lungs, because sparing β2 receptors spares the bronchi — the same β1-versus-β2 selectivity logic that governs cardioselective beta-blockers in the Cardiovascular section.

The systemic sting of a "local" drop

The drop is topical; the beta-blockade is not. Because so much drug is swallowed and absorbed, timolol produces genuine systemic beta-blockade, and its contraindications read like the contraindications of any oral beta-blocker taught in the Cardiovascular and Respiratory chapters. The dangerous one is the airway: blocking β2 receptors can trigger bronchospasm, and in a patient with asthma or significant COPD this can be severe and even fatal — non-selective topical beta-blockers are avoided outright in reactive airway disease. On the heart, β1 blockade causes bradycardia and can worsen or unmask heart block, so they are avoided in significant sinus bradycardia, second- or third-degree AV block, and decompensated heart failure. In diabetics they blunt the adrenergic warning signs of hypoglycaemia — the tremor and palpitations that tell a patient their sugar is crashing — so a hypo can arrive silently. Fatigue, reduced exercise tolerance, low mood and, occasionally, impotence round out the picture. Two mitigations matter: punctal occlusion with gentle eyelid closure for a minute cuts systemic absorption substantially, and choosing betaxolol (β1-selective) is the safer option when lung disease is present.

Carbonic anhydrase inhibitors: blocking the fluid factory

Aqueous secretion runs on bicarbonate, and bicarbonate runs on carbonic anhydrase. The enzyme carbonic anhydrase, sitting in the ciliary epithelium, catalyses the hydration of carbon dioxide to bicarbonate. That bicarbonate drives the osmotic gradient that pulls water into the posterior chamber to form aqueous. Inhibit the enzyme and bicarbonate formation falls, aqueous secretion drops, and pressure comes down. Two delivery routes exist. Topical CAIs — dorzolamide and brinzolamide — are used as chronic add-on drops; their local nuisances are a transient stinging or burning on instillation and a bitter taste (the drug reaching the palate down the same tear duct). Because they are applied to the eye, systemic effects are usually minor. The oral drug is a different animal: acetazolamide (and the older methazolamide) is a potent systemic CAI, reserved for short-term, heavy lifting.

Oral acetazolamide lowers pressure powerfully and fast, which makes it the workhorse for an acute intraocular pressure spike — most dramatically acute angle-closure glaucoma, the ophthalmic emergency, where it is given alongside topical agents and pilocarpine while the patient is rushed toward definitive laser or surgery. But acetazolamide is also, structurally, a diuretic — the original carbonic-anhydrase-inhibitor diuretic met in the Cardiovascular / Diuretics chapter — and it carries that whole systemic tail. It wastes bicarbonate in the kidney, producing a metabolic acidosis, and this drives the classic symptom of tingling paraesthesiae in the fingers, toes and around the mouth. It promotes potassium loss (hypokalaemia), can precipitate renal stones, and causes malaise, fatigue and gastrointestinal upset. Crucially, it is a sulfonamide, so it is avoided in patients with a true sulfa allergy — a caution that extends to the topical CAIs as well.